{"ticker": {"uuid": "49d93e28-5bb7-4128-b366-fddf9b154972", "symbol": "RZLT", "name": "Rezolute Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Form 4 Rezolute Inc For: 7 July By Investing.com", "summary": "The article reports on a Form 4 filing for Rezolute Inc., specifically for July 7th. Form 4s disclose transactions by company insiders, and this article provides a brief mention without detailing the specifics of the filing. It is primarily a placeholder announcement from Investi", "url": "https://ng.investing.com/news/stock-market-news/form-4-rezolute-inc-for-7-july-93CH-2589959", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T22:39:38", "published_display": "07 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) CMO disposes 3,062 shares in mandated RSU tax sale", "summary": "Rezolute, Inc.'s Chief Medical Officer, Brian Kenneth Roberts, reported a disposition of 3,062 common shares to cover tax withholding obligations related to vested Restricted Stock Units (RSUs). This transaction, valued at $4.99 per share, was a mandated \"sell to cover\" arrangeme", "url": "https://www.stocktitan.net/sec-filings/RZLT/form-4-rezolute-inc-insider-trading-activity-0b519964da60.html", "source_name": "Stock Titan", "published_at": "2026-07-07T22:39:37", "published_display": "07 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) CFO logs RSU tax sell-to-cover, retains 411,400 shares", "summary": "Rezolute, Inc.'s CFO, Daron Evans, reported a tax-related disposition of 3,062 common shares at $4.99 each. This \"sell-to-cover\" transaction was mandated by the company to satisfy tax withholding obligations related to Restricted Stock Unit vesting, not a discretionary trade. Fol", "url": "https://www.stocktitan.net/sec-filings/RZLT/form-4-rezolute-inc-insider-trading-activity-c0f907e2edb6.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:11:52", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) CEO logs automatic RSU tax-withholding share sale in Form 4", "summary": "Rezolute, Inc. CEO Nevan C. Elam reported an automatic sale of 8,004 common shares for $4.99 per share to cover tax withholding obligations from vested Restricted Stock Units. This was a mandatory \"sell to cover\" transaction, not a discretionary market trade. Following this dispo", "url": "https://www.stocktitan.net/sec-filings/RZLT/form-4-rezolute-inc-insider-trading-activity-0f20d85e6dc5.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:11:52", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RZLT - Rezolute Inc Options", "summary": "This article provides a detailed financial overview of Rezolute Inc (RZLT), including its last close price, market capitalization, income, sales, and various financial ratios. It also covers insider ownership, institutional ownership, quarterly and yearly EPS and sales performanc", "url": "https://finviz.com/stock?t=RZLT&ta=2&p=d&ty=oc&r=m6&ov=chain_strike&s=15", "source_name": "Finviz", "published_at": "2026-07-04T14:10:09", "published_display": "04 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rezolute, Inc. \u2013 NASDAQ:RZLT", "summary": "This article provides financial information for Rezolute, Inc. (NASDAQ: RZLT), specifically focusing on its forward price-to-sales ratio. It indicates that the company's market is currently closed with no trades recorded. The content seems to be a placeholder or a very brief data", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:42:12", "published_display": "29 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rezolute, Inc. \u2013 NASDAQ:RZLT", "summary": "This article provides a financial snapshot for Rezolute, Inc. (NASDAQ: RZLT), focusing on its forward price-to-earnings ratio. It indicates current market status as closed with no trades. The article is primarily a data page from TradingView, displaying basic company information ", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:09:55", "published_display": "29 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Rezolute, Inc. \u2013 NASDAQ:RZLT", "summary": "This article provides access to the \"Price to book forward\" metric for Rezolute, Inc. (NASDAQ: RZLT). It appears to be a financial data page from TradingView, offering an overview of the company's financial information.", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T06:41:08", "published_display": "29 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rezolute, Inc. \u2013 DUS:6HV1", "summary": "This article provides the enterprise value to revenue forward for Rezolute, Inc. (DUS:6HV1) on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades. The content primarily serves as a financial data point without further analysis or detail", "url": "https://www.tradingview.com/symbols/DUS-6HV1/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:09:55", "published_display": "29 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rezolute, Inc. \u2013 DUS:6HV1", "summary": "The article mentions the \"Price to earnings forward\" metric for Rezolute, Inc. (DUS:6HV1), listed on the Dusseldorf Stock Exchange. It indicates no current trading activity for the stock, as the market is closed and no trades have occurred. The content is presented as a financial", "url": "https://www.tradingview.com/symbols/DUS-6HV1/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T22:39:49", "published_display": "28 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rezolute, Inc. \u2013 NASDAQ:RZLT", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Rezolute, Inc. (NASDAQ: RZLT). It is a brief financial snippet provided by TradingView, indicating a key valuation ratio for the company's stock. The content itself provides very little information beyon", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:17", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute, Inc. Actuals & Estimates (NASDAQ:RZLT)", "summary": "This article provides an in-depth financial overview of Rezolute, Inc. (NASDAQ: RZLT), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It includes information on market capitalization, earnings, revenue, and employee count,", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:10:31", "published_display": "25 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14", "summary": "This article provides a quick look at analyst ratings for Rezolute (RZLT.US), noting a forecast price range between $5 and $14. Further details on the specific ratings and what informs this forecast were not available in the provided content.", "url": "https://www.moomoo.com/news/post/71066537/a-quick-look-at-today-s-ratings-for-rezolute-rzltus", "source_name": "Moomoo", "published_at": "2026-06-25T03:09:49", "published_display": "25 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth", "summary": "Rezolute Inc. is making significant progress with its late-stage drug Ersodetug, targeting rare forms of hypoglycemia caused by hyperinsulinism. Recent data presented at ENDO 2026 and positive analyst ratings underscore the drug's potential in congenital and tumor-related hyperin", "url": "https://www.streetwisereports.com/article/2026/06/20/rezolutes-ersodetug-advances-in-rare-hypoglycemia-treatment-amid-pharma-growth.html", "source_name": "Streetwise Reports", "published_at": "2026-06-20T15:08:58", "published_display": "20 Jun 2026 15:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Rezolute stock price target on trial outlook", "summary": "Guggenheim has increased its price target for Rezolute Inc. (NASDAQ:RZLT) to $11 from $6, maintaining a Buy rating. This adjustment is based on the strong likelihood of positive results from the upLIFT registrational study in the latter half of 2026, with an interim update de-ris", "url": "https://www.investing.com/news/analyst-ratings/guggenheim-raises-rezolute-stock-price-target-on-trial-outlook-93CH-4741891", "source_name": "Investing.com", "published_at": "2026-06-20T06:40:05", "published_display": "20 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data", "summary": "Rezolute Inc. (RZLT:NASDAQ) presented encouraging data for its hypoglycemia treatment, ersodetug, at ENDO 2026, gaining attention from analysts who predict significant gains and a \"Buy\" rating. The company focuses on refractory hypoglycemia caused by hyperinsulinism and expects P", "url": "https://www.streetwisereports.com/article/2026/06/19/biopharma-developer-unveils-breakthrough-hypoglycemia-treatment-data.html", "source_name": "Streetwise Reports", "published_at": "2026-06-19T15:39:15", "published_display": "19 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Rezolute Inc (RZLT), detailing its current price momentum score, support and resistance levels. It also presents a summary of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages, indicating a 'Buy' signal based on ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rzlt/technical", "source_name": "TradingKey", "published_at": "2026-06-19T05:10:39", "published_display": "19 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Inc (RZLT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Rezolute Inc (RZLT)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also presents current stock performance details for", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rzlt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:44", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Inc (RZLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Rezolute Inc (RZLT). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The article primarily displays general compa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rzlt/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:47", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society", "summary": "Rezolute, Inc. presented data at the Annual Meeting of the Endocrine Society on natural history outcomes in congenital hyperinsulinism (HI) and its ersodetug clinical program. Presentations included analyses of adverse outcomes in congenital HI, favorable results from an Expanded", "url": "https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society/2367372/amp", "source_name": "The Manila Times", "published_at": "2026-06-17T11:39:47", "published_display": "17 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute data: 75% of tumor HI patients came off IV dextrose at ENDO", "summary": "Rezolute (Nasdaq: RZLT) announced that 75% of tumor hyperinsulinism (HI) patients in its Expanded Access Program (EAP) were able to discontinue IV dextrose/TPN support, as presented at the annual ENDO meeting. The company highlighted four presentations covering congenital and tum", "url": "https://www.stocktitan.net/news/RZLT/rezolute-highlights-results-presented-from-natural-history-outcomes-8vyr3w1e5rhe.html", "source_name": "Stock Titan", "published_at": "2026-06-17T11:03:18", "published_display": "17 Jun 2026 11:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Rezolute Inc's (RZLT) earnings forecast score is 8.20, ranking 153 out of 388 in its industry. Analysts have set an average price target of $17.00 for RZLT, with a strong \"Buy\" consensus rating based on 10 analysts. The previous quarter's EPS was -$0.22 against an expectation of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rzlt/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T10:39:19", "published_display": "17 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD)", "summary": "Three analysts from H.C. Wainwright have issued bullish sentiments on healthcare companies Brainsway (BWAY), Rezolute (RZLT), and Invivyd (IVVD). Ram Selvaraju reiterated a Buy rating for Brainsway with a $17.00 price target, Douglas Tsao assigned a Buy rating for Rezolute with a", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2488070/analysts-offer-insights-on-healthcare-companies-brainsway-bway-rezolute-rzlt-and-invivyd-ivvd/", "source_name": "The Globe and Mail", "published_at": "2026-06-16T10:33:23", "published_display": "16 Jun 2026 10:33", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RZLT Maintained by Guggenheim -- Price Target Raised to $11.00", "summary": "Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Rezolute (RZLT) and significantly raised the price target to $11.00 from $6.00, representing an 83.33% increase. The company, a clinical-stage biopharmaceutical firm, is currently trading at $4.34, suggestin", "url": "https://www.gurufocus.com/news/8916635/rzlt-maintained-by-guggenheim-price-target-raised-to-1100", "source_name": "GuruFocus", "published_at": "2026-06-15T16:40:14", "published_display": "15 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploring 3 High Growth Tech Stocks in US Market", "summary": "This article identifies three high-growth tech stocks in the US market: Rezolute (RZLT), SELLAS Life Sciences Group (SLS), and Larimar Therapeutics (LRMR). It provides an overview of each company, their current operations, and highlights their growth potential, innovative treatme", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/exploring-3-high-growth-tech-stocks-in-us-market-3", "source_name": "Simply Wall Street", "published_at": "2026-06-15T11:40:14", "published_display": "15 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Rezolute stock price target on trial outlook By Investing.com", "summary": "Guggenheim has increased its price target for Rezolute Inc. (NASDAQ: RZLT) from $6 to $11, maintaining a Buy rating, citing confidence in a positive outcome from the upLIFT registrational study in the latter half of 2026. The firm projects approximately $850 million in peak sales", "url": "https://ca.investing.com/news/stock-market-news/guggenheim-raises-rezolute-stock-price-target-on-trial-outlook-93CH-4690567", "source_name": "Investing.com Canada", "published_at": "2026-06-15T11:40:14", "published_display": "15 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Signs As Multiple Insiders Buy Rezolute Stock", "summary": "Multiple insider purchases of Rezolute, Inc. (NASDAQ:RZLT) stock have been observed, signaling a positive outlook from company executives. Although individual purchases may not be significant, the collective buying suggests insiders view the stock favorably, particularly after a ", "url": "https://uk.finance.yahoo.com/news/positive-signs-multiple-insiders-buy-114623068.html", "source_name": "Market source", "published_at": "2026-06-10T11:40:07", "published_display": "10 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rezolute-announces-four-presentations-upcoming-113000049.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T11:30:00+00:00", "published_display": "04 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-adjusts-price-target-rezolute-110018692.html", "source_name": "MT Newswires", "published_at": "2026-06-03T11:00:18+00:00", "published_display": "03 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute\u2019s stock up on interim Phase III tumour HI data", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOVU9jWDFyaC1VV2NwZjBUOVZNbl95Q3ZTM3lRSWxXRXd6a2gtVFlXWDFZa2xaVlFMVDhCTndEZkV0NGw3Nmw3RkktVm5meWl5QVRBaXBsTmpFUjZPVWVaMkZybmwyZ2pjN01MLUlBSG9JTHJEbVVuYUYybENXTDdtcG8yVjdxd2I5T3hBRGtQLS1RcGtydHZiYjJKMGFjQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rezolute-shares-rise-participants-meet-181641416.html", "source_name": "MT Newswires", "published_at": "2026-06-02T18:16:41+00:00", "published_display": "02 Jun 2026 18:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Says 6 Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rezolute-says-6-participants-meet-122501209.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:25:01+00:00", "published_display": "02 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute rises after late-stage trial update (RZLT:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOZWwtZFJTRFNGaXVyZTAtY0FPa2JCNVNGOFRrbGlGM2xEQzl3SHdUQnVQV25jWEduWTlacTN4Z1FjaVllaldmNy1vWUNzSUV4aU02VGZiZlJzUlNaQ0NqUXo2eG52Yl9Yc0hnQnZZUGV1SlJKbTBxRWRycXVmbXRJWGxzSk5HRV9qYUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Opaleye-affiliated holders report 6.3M shares in Rezolute (RZLT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQWUpFMkh3VDJBNG4tUy12TDJ5aTFlNFlqaGdqam43ZHV4M1NQVW0yN2E1b2ZJTGZSdUN5ajRSVVptVHpMc0ZETi1tY3Y1XzVNVVQ5dzBDbzFTYkpsanN2MWlRWEZuQWZvbDkwY0RzbDdrWmd0XzFGdXAzMnh0U0RPRzBXc1E2YmpPTTVMMDBXQl8ybmtSSmNSYkZlZkc0dGpyU0dxRFhUbFhuYjl5bGhwNjNZY19nTC15YU1kU0Q4NU5aQVByZnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Rezolute gains after positive FDA meeting over lead asset", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBoSm8xbGFMbXI2ci1RWGRMNElsYUxsdzF4eGFuM2M1Z1doajMwS2hqajlyTXdYc3VwX2VacHBVYk5rUEExYVZ5SFVQT1VwbUF1SV9Xa2pta1FlM1M4ZVlhakx4SU0wNjlELU9zeFhSUlNjWnlwTnVKYU5zTnF0QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) Valuation Revisited After Phase 3 sunRIZE Trial Misses Primary and Key Secondary Endpoints", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxOQ2p3cnpLeVdDWko1UEI0cUZ0NTBDNC1SanFiTXBvVXBHWGE5RnYwVHc5UlRKdEppU1lNWDBxVXBId3VYemtWeXlsS0pRbEpBTDRSVEJEM2JFMVBzdHQwdTl2dGk0V1lSMWpQQmYwODByU2JQQUd5WnhkUzl0TE1BcHhPRUtydGo1Ry1MWWdrcVp1c0pXc1AxNG1odUQtWnVpMU1VLThyVS1LNmwxRzZMb2EwNVpsOTE1M3NNOEdMdGtuU1R6M05VWDdwZVY0cW1fOFZpQU1ETHFETkw0V1dOMmpRYw?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBsVFlDWHdPM25QSzVEZEs1Y0N0QW1kMFE2bXVpbEpURkZaczdBVlpmVGRzcmtDWW5xWlgwYmFNaVM0Z09yUFg5Z0YyMGRWcmk3MFc4UC1YWVdBaERBU1l6UUphQ3FFS2xSclloUnFITkU?oc=5", "source_name": "Market source", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) Is Down 82.7% After Phase 3 sunRIZE Failure in Congenital Hyperinsulinism Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE53ek84dGc5eWt0eHJpOEY3SC1zZXFiT2Z0c1N1SmozMUlQREQzOUNZMkdZU1pneV9CclpvdGVDZDlscGFERkwxdWFZVjFtVU1RQ0dETWNQVFFSclE1YzYyb1BOb1ZRVXVqU2ZOdEhqTlVKSmtrQ2Rjaw?oc=5", "source_name": "Market source", "published_at": "2025-12-14T08:00:00+00:00", "published_display": "14 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute, Inc. (RZLT) Investigation", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE1YTzVuQ0VKbXplSFo4c2dmQ01jWE15RWE5NmJMTW1IU2hjWW1WallEb0F5aW51dFlIMzBBZTJIRDBFSS1MUTFPVV8zdXN2ZlZTUmdvdGxDMTJRRDVEMldma2xaUUVFY2pDVWlkYjJB?oc=5", "source_name": "Hagens Berman", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 4 Rezolute Inc For: 7 July By Investing.com", "summary": "The article reports on a Form 4 filing for Rezolute Inc., specifically for July 7th. Form 4s disclose transactions by company insiders, and this article provides a brief mention without detailing the specifics of the filing. It is primarily a placeholder announcement from Investi", "url": "https://ng.investing.com/news/stock-market-news/form-4-rezolute-inc-for-7-july-93CH-2589959", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T22:39:38", "published_display": "07 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) CMO disposes 3,062 shares in mandated RSU tax sale", "summary": "Rezolute, Inc.'s Chief Medical Officer, Brian Kenneth Roberts, reported a disposition of 3,062 common shares to cover tax withholding obligations related to vested Restricted Stock Units (RSUs). This transaction, valued at $4.99 per share, was a mandated \"sell to cover\" arrangeme", "url": "https://www.stocktitan.net/sec-filings/RZLT/form-4-rezolute-inc-insider-trading-activity-0b519964da60.html", "source_name": "Stock Titan", "published_at": "2026-07-07T22:39:37", "published_display": "07 Jul 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) CFO logs RSU tax sell-to-cover, retains 411,400 shares", "summary": "Rezolute, Inc.'s CFO, Daron Evans, reported a tax-related disposition of 3,062 common shares at $4.99 each. This \"sell-to-cover\" transaction was mandated by the company to satisfy tax withholding obligations related to Restricted Stock Unit vesting, not a discretionary trade. Fol", "url": "https://www.stocktitan.net/sec-filings/RZLT/form-4-rezolute-inc-insider-trading-activity-c0f907e2edb6.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:11:52", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) CEO logs automatic RSU tax-withholding share sale in Form 4", "summary": "Rezolute, Inc. CEO Nevan C. Elam reported an automatic sale of 8,004 common shares for $4.99 per share to cover tax withholding obligations from vested Restricted Stock Units. This was a mandatory \"sell to cover\" transaction, not a discretionary market trade. Following this dispo", "url": "https://www.stocktitan.net/sec-filings/RZLT/form-4-rezolute-inc-insider-trading-activity-0f20d85e6dc5.html", "source_name": "Stock Titan", "published_at": "2026-07-07T21:11:52", "published_display": "07 Jul 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RZLT - Rezolute Inc Options", "summary": "This article provides a detailed financial overview of Rezolute Inc (RZLT), including its last close price, market capitalization, income, sales, and various financial ratios. It also covers insider ownership, institutional ownership, quarterly and yearly EPS and sales performanc", "url": "https://finviz.com/stock?t=RZLT&ta=2&p=d&ty=oc&r=m6&ov=chain_strike&s=15", "source_name": "Finviz", "published_at": "2026-07-04T14:10:09", "published_display": "04 Jul 2026 14:10", "sentiment": "negative", "sentiment_pct": 41, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Rezolute, Inc. \u2013 NASDAQ:RZLT", "summary": "This article provides financial information for Rezolute, Inc. (NASDAQ: RZLT), specifically focusing on its forward price-to-sales ratio. It indicates that the company's market is currently closed with no trades recorded. The content seems to be a placeholder or a very brief data", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:42:12", "published_display": "29 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rezolute, Inc. \u2013 NASDAQ:RZLT", "summary": "This article provides a financial snapshot for Rezolute, Inc. (NASDAQ: RZLT), focusing on its forward price-to-earnings ratio. It indicates current market status as closed with no trades. The article is primarily a data page from TradingView, displaying basic company information ", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T19:09:55", "published_display": "29 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Rezolute, Inc. \u2013 NASDAQ:RZLT", "summary": "This article provides access to the \"Price to book forward\" metric for Rezolute, Inc. (NASDAQ: RZLT). It appears to be a financial data page from TradingView, offering an overview of the company's financial information.", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T06:41:08", "published_display": "29 Jun 2026 06:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rezolute, Inc. \u2013 DUS:6HV1", "summary": "This article provides the enterprise value to revenue forward for Rezolute, Inc. (DUS:6HV1) on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades. The content primarily serves as a financial data point without further analysis or detail", "url": "https://www.tradingview.com/symbols/DUS-6HV1/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T05:09:55", "published_display": "29 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Rezolute, Inc. \u2013 DUS:6HV1", "summary": "The article mentions the \"Price to earnings forward\" metric for Rezolute, Inc. (DUS:6HV1), listed on the Dusseldorf Stock Exchange. It indicates no current trading activity for the stock, as the market is closed and no trades have occurred. The content is presented as a financial", "url": "https://www.tradingview.com/symbols/DUS-6HV1/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T22:39:49", "published_display": "28 Jun 2026 22:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Rezolute, Inc. \u2013 NASDAQ:RZLT", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Rezolute, Inc. (NASDAQ: RZLT). It is a brief financial snippet provided by TradingView, indicating a key valuation ratio for the company's stock. The content itself provides very little information beyon", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T09:39:17", "published_display": "28 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute, Inc. Actuals & Estimates (NASDAQ:RZLT)", "summary": "This article provides an in-depth financial overview of Rezolute, Inc. (NASDAQ: RZLT), detailing its current stock price, historical performance, analyst forecasts, and key financial metrics. It includes information on market capitalization, earnings, revenue, and employee count,", "url": "https://www.tradingview.com/symbols/NASDAQ-RZLT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T21:10:31", "published_display": "25 Jun 2026 21:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Quick Look at Today's Ratings for Rezolute(RZLT.US), With a Forecast Between $5 to $14", "summary": "This article provides a quick look at analyst ratings for Rezolute (RZLT.US), noting a forecast price range between $5 and $14. Further details on the specific ratings and what informs this forecast were not available in the provided content.", "url": "https://www.moomoo.com/news/post/71066537/a-quick-look-at-today-s-ratings-for-rezolute-rzltus", "source_name": "Moomoo", "published_at": "2026-06-25T03:09:49", "published_display": "25 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute's Ersodetug Advances in Rare Hypoglycemia Treatment Amid Pharma Growth", "summary": "Rezolute Inc. is making significant progress with its late-stage drug Ersodetug, targeting rare forms of hypoglycemia caused by hyperinsulinism. Recent data presented at ENDO 2026 and positive analyst ratings underscore the drug's potential in congenital and tumor-related hyperin", "url": "https://www.streetwisereports.com/article/2026/06/20/rezolutes-ersodetug-advances-in-rare-hypoglycemia-treatment-amid-pharma-growth.html", "source_name": "Streetwise Reports", "published_at": "2026-06-20T15:08:58", "published_display": "20 Jun 2026 15:08", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Rezolute stock price target on trial outlook", "summary": "Guggenheim has increased its price target for Rezolute Inc. (NASDAQ:RZLT) to $11 from $6, maintaining a Buy rating. This adjustment is based on the strong likelihood of positive results from the upLIFT registrational study in the latter half of 2026, with an interim update de-ris", "url": "https://www.investing.com/news/analyst-ratings/guggenheim-raises-rezolute-stock-price-target-on-trial-outlook-93CH-4741891", "source_name": "Investing.com", "published_at": "2026-06-20T06:40:05", "published_display": "20 Jun 2026 06:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biopharma Developer Unveils Breakthrough Hypoglycemia Treatment Data", "summary": "Rezolute Inc. (RZLT:NASDAQ) presented encouraging data for its hypoglycemia treatment, ersodetug, at ENDO 2026, gaining attention from analysts who predict significant gains and a \"Buy\" rating. The company focuses on refractory hypoglycemia caused by hyperinsulinism and expects P", "url": "https://www.streetwisereports.com/article/2026/06/19/biopharma-developer-unveils-breakthrough-hypoglycemia-treatment-data.html", "source_name": "Streetwise Reports", "published_at": "2026-06-19T15:39:15", "published_display": "19 Jun 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Inc (RZLT) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Rezolute Inc (RZLT), detailing its current price momentum score, support and resistance levels. It also presents a summary of various technical indicators (MACD, RSI, KDJ, etc.) and moving averages, indicating a 'Buy' signal based on ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rzlt/technical", "source_name": "TradingKey", "published_at": "2026-06-19T05:10:39", "published_display": "19 Jun 2026 05:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Inc (RZLT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Rezolute Inc (RZLT)'s dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also presents current stock performance details for", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rzlt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:40:44", "published_display": "17 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Inc (RZLT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for Rezolute Inc (RZLT). However, it states that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The article primarily displays general compa", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rzlt/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T20:39:47", "published_display": "17 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society", "summary": "Rezolute, Inc. presented data at the Annual Meeting of the Endocrine Society on natural history outcomes in congenital hyperinsulinism (HI) and its ersodetug clinical program. Presentations included analyses of adverse outcomes in congenital HI, favorable results from an Expanded", "url": "https://www.manilatimes.net/2026/06/17/tmt-newswire/globenewswire/rezolute-highlights-results-presented-from-natural-history-outcomes-studies-and-its-ersodetug-clinical-program-in-hyperinsulinism-at-annual-meeting-of-the-endocrine-society/2367372/amp", "source_name": "The Manila Times", "published_at": "2026-06-17T11:39:47", "published_display": "17 Jun 2026 11:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute data: 75% of tumor HI patients came off IV dextrose at ENDO", "summary": "Rezolute (Nasdaq: RZLT) announced that 75% of tumor hyperinsulinism (HI) patients in its Expanded Access Program (EAP) were able to discontinue IV dextrose/TPN support, as presented at the annual ENDO meeting. The company highlighted four presentations covering congenital and tum", "url": "https://www.stocktitan.net/news/RZLT/rezolute-highlights-results-presented-from-natural-history-outcomes-8vyr3w1e5rhe.html", "source_name": "Stock Titan", "published_at": "2026-06-17T11:03:18", "published_display": "17 Jun 2026 11:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Inc (RZLT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Rezolute Inc's (RZLT) earnings forecast score is 8.20, ranking 153 out of 388 in its industry. Analysts have set an average price target of $17.00 for RZLT, with a strong \"Buy\" consensus rating based on 10 analysts. The previous quarter's EPS was -$0.22 against an expectation of ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-rzlt/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T10:39:19", "published_display": "17 Jun 2026 10:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Brainsway (BWAY), Rezolute (RZLT) and Invivyd (IVVD)", "summary": "Three analysts from H.C. Wainwright have issued bullish sentiments on healthcare companies Brainsway (BWAY), Rezolute (RZLT), and Invivyd (IVVD). Ram Selvaraju reiterated a Buy rating for Brainsway with a $17.00 price target, Douglas Tsao assigned a Buy rating for Rezolute with a", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2488070/analysts-offer-insights-on-healthcare-companies-brainsway-bway-rezolute-rzlt-and-invivyd-ivvd/", "source_name": "The Globe and Mail", "published_at": "2026-06-16T10:33:23", "published_display": "16 Jun 2026 10:33", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RZLT Maintained by Guggenheim -- Price Target Raised to $11.00", "summary": "Guggenheim analyst Debjit Chattopadhyay has maintained a 'Buy' rating on Rezolute (RZLT) and significantly raised the price target to $11.00 from $6.00, representing an 83.33% increase. The company, a clinical-stage biopharmaceutical firm, is currently trading at $4.34, suggestin", "url": "https://www.gurufocus.com/news/8916635/rzlt-maintained-by-guggenheim-price-target-raised-to-1100", "source_name": "GuruFocus", "published_at": "2026-06-15T16:40:14", "published_display": "15 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exploring 3 High Growth Tech Stocks in US Market", "summary": "This article identifies three high-growth tech stocks in the US market: Rezolute (RZLT), SELLAS Life Sciences Group (SLS), and Larimar Therapeutics (LRMR). It provides an overview of each company, their current operations, and highlights their growth potential, innovative treatme", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rzlt/rezolute/news/exploring-3-high-growth-tech-stocks-in-us-market-3", "source_name": "Simply Wall Street", "published_at": "2026-06-15T11:40:14", "published_display": "15 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Guggenheim raises Rezolute stock price target on trial outlook By Investing.com", "summary": "Guggenheim has increased its price target for Rezolute Inc. (NASDAQ: RZLT) from $6 to $11, maintaining a Buy rating, citing confidence in a positive outcome from the upLIFT registrational study in the latter half of 2026. The firm projects approximately $850 million in peak sales", "url": "https://ca.investing.com/news/stock-market-news/guggenheim-raises-rezolute-stock-price-target-on-trial-outlook-93CH-4690567", "source_name": "Investing.com Canada", "published_at": "2026-06-15T11:40:14", "published_display": "15 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 74, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Positive Signs As Multiple Insiders Buy Rezolute Stock", "summary": "Multiple insider purchases of Rezolute, Inc. (NASDAQ:RZLT) stock have been observed, signaling a positive outlook from company executives. Although individual purchases may not be significant, the collective buying suggests insiders view the stock favorably, particularly after a ", "url": "https://uk.finance.yahoo.com/news/positive-signs-multiple-insiders-buy-114623068.html", "source_name": "Market source", "published_at": "2026-06-10T11:40:07", "published_display": "10 Jun 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rezolute-announces-four-presentations-upcoming-113000049.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T11:30:00+00:00", "published_display": "04 Jun 2026 11:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/wedbush-adjusts-price-target-rezolute-110018692.html", "source_name": "MT Newswires", "published_at": "2026-06-03T11:00:18+00:00", "published_display": "03 Jun 2026 11:00", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute\u2019s stock up on interim Phase III tumour HI data", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxOVU9jWDFyaC1VV2NwZjBUOVZNbl95Q3ZTM3lRSWxXRXd6a2gtVFlXWDFZa2xaVlFMVDhCTndEZkV0NGw3Nmw3RkktVm5meWl5QVRBaXBsTmpFUjZPVWVaMkZybmwyZ2pjN01MLUlBSG9JTHJEbVVuYUYybENXTDdtcG8yVjdxd2I5T3hBRGtQLS1RcGtydHZiYjJKMGFjQQ?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Update: Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rezolute-shares-rise-participants-meet-181641416.html", "source_name": "MT Newswires", "published_at": "2026-06-02T18:16:41+00:00", "published_display": "02 Jun 2026 18:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute Says 6 Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rezolute-says-6-participants-meet-122501209.html", "source_name": "MT Newswires", "published_at": "2026-06-02T12:25:01+00:00", "published_display": "02 Jun 2026 12:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute rises after late-stage trial update (RZLT:NASDAQ)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOZWwtZFJTRFNGaXVyZTAtY0FPa2JCNVNGOFRrbGlGM2xEQzl3SHdUQnVQV25jWEduWTlacTN4Z1FjaVllaldmNy1vWUNzSUV4aU02VGZiZlJzUlNaQ0NqUXo2eG52Yl9Yc0hnQnZZUGV1SlJKbTBxRWRycXVmbXRJWGxzSk5HRV9qYUE?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opaleye-affiliated holders report 6.3M shares in Rezolute (RZLT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQWUpFMkh3VDJBNG4tUy12TDJ5aTFlNFlqaGdqam43ZHV4M1NQVW0yN2E1b2ZJTGZSdUN5ajRSVVptVHpMc0ZETi1tY3Y1XzVNVVQ5dzBDbzFTYkpsanN2MWlRWEZuQWZvbDkwY0RzbDdrWmd0XzFGdXAzMnh0U0RPRzBXc1E2YmpPTTVMMDBXQl8ybmtSSmNSYkZlZkc0dGpyU0dxRFhUbFhuYjl5bGhwNjNZY19nTC15YU1kU0Q4NU5aQVByZnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute gains after positive FDA meeting over lead asset", "summary": "", "url": "https://news.google.com/rss/articles/CBMifkFVX3lxTFBoSm8xbGFMbXI2ci1RWGRMNElsYUxsdzF4eGFuM2M1Z1doajMwS2hqajlyTXdYc3VwX2VacHBVYk5rUEExYVZ5SFVQT1VwbUF1SV9Xa2pta1FlM1M4ZVlhakx4SU0wNjlELU9zeFhSUlNjWnlwTnVKYU5zTnF0QQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) Valuation Revisited After Phase 3 sunRIZE Trial Misses Primary and Key Secondary Endpoints", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-25T08:00:00+00:00", "published_display": "25 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxOQ2p3cnpLeVdDWko1UEI0cUZ0NTBDNC1SanFiTXBvVXBHWGE5RnYwVHc5UlRKdEppU1lNWDBxVXBId3VYemtWeXlsS0pRbEpBTDRSVEJEM2JFMVBzdHQwdTl2dGk0V1lSMWpQQmYwODByU2JQQUd5WnhkUzl0TE1BcHhPRUtydGo1Ry1MWWdrcVp1c0pXc1AxNG1odUQtWnVpMU1VLThyVS1LNmwxRzZMb2EwNVpsOTE1M3NNOEdMdGtuU1R6M05VWDdwZVY0cW1fOFZpQU1ETHFETkw0V1dOMmpRYw?oc=5", "source_name": "PR Newswire", "published_at": "2025-12-23T08:00:00+00:00", "published_display": "23 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 81.8% in 4 Weeks, Here's Why Rezolute (RZLT) Looks Ripe for a Turnaround", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTFBsVFlDWHdPM25QSzVEZEs1Y0N0QW1kMFE2bXVpbEpURkZaczdBVlpmVGRzcmtDWW5xWlgwYmFNaVM0Z09yUFg5Z0YyMGRWcmk3MFc4UC1YWVdBaERBU1l6UUphQ3FFS2xSclloUnFITkU?oc=5", "source_name": "Market source", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute (RZLT) Is Down 82.7% After Phase 3 sunRIZE Failure in Congenital Hyperinsulinism Trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMieEFVX3lxTE53ek84dGc5eWt0eHJpOEY3SC1zZXFiT2Z0c1N1SmozMUlQREQzOUNZMkdZU1pneV9CclpvdGVDZDlscGFERkwxdWFZVjFtVU1RQ0dETWNQVFFSclE1YzYyb1BOb1ZRVXVqU2ZOdEhqTlVKSmtrQ2Rjaw?oc=5", "source_name": "Market source", "published_at": "2025-12-14T08:00:00+00:00", "published_display": "14 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rezolute, Inc. (RZLT) Investigation", "summary": "", "url": "https://news.google.com/rss/articles/CBMibkFVX3lxTE1YTzVuQ0VKbXplSFo4c2dmQ01jWE15RWE5NmJMTW1IU2hjWW1WallEb0F5aW51dFlIMzBBZTJIRDBFSS1MUTFPVV8zdXN2ZlZTUmdvdGxDMTJRRDVEMldma2xaUUVFY2pDVWlkYjJB?oc=5", "source_name": "Hagens Berman", "published_at": "2025-12-11T08:00:00+00:00", "published_display": "11 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 93, "total_relevant": 49, "sentiment_summary": {"positive": 15, "negative": 4, "neutral": 30, "score": 57, "total": 49, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 11.7, "count": 20}, {"event": "earnings", "label": "Earnings", "weight": 8.25, "count": 17}, {"event": "analyst", "label": "Analyst action", "weight": 3.3, "count": 6}, {"event": "guidance", "label": "Guidance", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 15, "negative_events": 4}, "market_context": {"has_market_context": true, "latest_close": 4.75, "latest_week": "2026-07-10", "one_week_move": -3.3, "four_week_move": 18.8, "twelve_week_move": 37.3, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.823193, "market_dynamics_buy_signal": false, "relative_strength": -23.993702, "fair_value_gap": 21.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 50.229, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.3% over one week, +18.8% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 9}, {"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 5}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "Streetwise Reports", "count": 2}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 41}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 20}, {"label": "Earnings", "count": 17}, {"label": "Analyst action", "count": 6}, {"label": "Guidance", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Regulatory and legal", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "41", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.3% over one week, +18.8% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 4 Rezolute Inc For: 7 July By Investing.com"}], "updated_at": "2026-07-16T08:12:00.398401+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}